Search by...
-
17JulViviana Sterlocchi appointed Chief Marketing Officer at Portolano CavalloWith this appointment, Portolano Cavallo reaffirms its strategic focus on enhancing managerial capabilities to navigate an increasingly competitive legal market.
-
3JunPAD, how to certify digital procurement platformsLa vendita di farmaci online comporta il trattamento di dati personali che possono essere qualificati come dati sulla salute secondo il GDPR, richiedendo specifiche cautele e obblighi per gli operatori del settore
-
-
29AprPolitica dei dazi nella nuova amministrazione USA: alcune prime riflessioni sugli impatti legali ed operativi per le impreseNell'iniziale scenario di guerra commerciale avviato da Trump attraverso l'imposizione di una politica a rialzo di dazi, le principali economie europee e mondiali si interrogano sull'impatto dell'introduzione di tali misure e su come poter reagire efficacemente.
-
-
7AprPortolano Cavallo announces the appointment of Daniela Amhof and Donata Cordone as partnersWith the promotion of Amhof and Cordone, the number of partners rises to 23, including 11 women: a female equity presence that is unique in Italy.
-
4DecPortolano Cavallo appoints Pablo Fernando Ambrosy Carrera Chief Digital and Innovation OfficerPablo Fernando Ambrosy Carrera joining the team is another sign of the firm’s commitment to digital innovation
-
9OctFarmaci anticontraffazione: entro il 9 febbraio 2025 l’Italia deve adeguarsi al Regolamento Ue 2016/161Measures to combat counterfeit drugs work to prevent such drugs from entering the European supply chain. Delegated Regulation (EU) 2016/161 introduces new rules to halt counterfeit drugs from entering the European market and includes digital tools. As of February 9, 2025, Italy will have to comply with the provisions of the regulation, so there is not much time left to get in line with the new measures.
-
-
25SepNew Aifa guidelines on observational studies and decentralized clinical trials: digital tools increasingly in focusThe AIFA issued two new guidelines, focusing, respectively, on observational studies and clinical trials for medicinal products.
-
-
23SepNew Aifa guidelines on clinical trials between simplification and decentralizationAs mentioned in our other article, this article deals with the guidelines approved by the AIFA on the same day as those on observational studies. They were also published in the Italian Official Gazette on August 20, 2024. The guidelines concern simplification and decentralization of clinical trials of medicines.
-
-
16SepPAD, how to certify digital procurement platformsCome affrontare l’iter di certificazione delle PAD, le piattaforme di approvvigionamento digitali: ecco una guida completa con tutte le indicazioni per non sbagliare
-
-
4SepThe DABUS Case: Artificial Intelligence Cannot Be Designated as an Inventor on a PatentArtificial intelligence (AI) plays a fundamental role in the life sciences sector. AI offers the opportunity to facilitate various processes. For example, it can be used to analyze and process large quantities of health data that in turn may facilitate the discovery of new drugs, improve diagnostics, and customize treatments. It also can be used to automate laboratory processes and manage clinical trials, saving time and resources.
-
